Nature’s Sunshine to acquire full ownership of China joint ventures after Fosun Pharma stake sale

Nature's Sunshine Products (NATR) is consolidating its China operations by acquiring the remaining 20% stakes in its two joint ventures from Fosun Industrial for $7 million, a move triggered by Fosun Pharma's recent share divestment below 5%. Concurrently, Fosun Pharma USA is conducting a secondary offering of 2.85 million NATR shares at $12.00, with NATR holding a $15 million repurchase option. This strategic consolidation and capital allocation initiative is supported by DA Davidson, which reiterated a Buy rating and raised NATR's price target to $20.00, citing strong gross margins, a clean balance sheet, and digital growth drivers.

Analysis

Nature’s Sunshine Products (NATR) is executing a strategic consolidation of its China operations by acquiring the remaining 20% interests in its Hong Kong and Shanghai joint ventures from Fosun Industrial for a total of $7 million in cash. This transaction, which will grant NATR full ownership and control, was triggered by Fosun Pharma's divestment of its stake in NATR to below 5%. Concurrent with this operational move, Fosun's affiliate is conducting a secondary offering of 2,854,607 shares at $12.00 per share, providing an orderly exit for the major shareholder. While NATR will not receive proceeds, the company has opportunistically secured the right to repurchase up to $15 million of these shares, signaling confidence and a commitment to capital returns. The strategic rationale is supported by strong underlying fundamentals, including an impressive gross profit margin of 71.7% and a clean balance sheet. This positive outlook is echoed by DA Davidson, which reiterated a Buy rating and raised its price target to $20.00, citing the company's digital-first strategy and potential for volume leverage as key growth drivers. The completion of the joint venture acquisitions remains contingent on regulatory approvals in China.

Key Decisions for Investors

• Investors should view the full buyout of the Chinese joint ventures as a significant positive, as it solidifies control over a key market and captures all future earnings from the region.
• The secondary offering at $12.00 provides clarity on the exit of a major shareholder, while the company's $15 million share repurchase option at that price could be accretive and provide a level of support for the stock.
• Given the combination of strong fundamentals, including a 71.7% gross margin, and a raised analyst price target of $20.00, the current market valuation may present an attractive opportunity.
• Monitor the transaction's progress, as its completion is subject to regulatory approval from Chinese authorities, which represents a key near-term condition for realizing the deal's benefits.